Clinical responses of patients with Kawasaki Disease to different brands of intravenous immunoglobulin

Ming Han Tsai, Yhu Chering Huang, Meng Hsiu Yen, Chung Chen Li, Cheng Hsun Chiu, Pen Yi Lin, Tzou Yien Lin, Luan Yin Chang

研究成果: 雜誌貢獻文章同行評審

39 引文 斯高帕斯(Scopus)


Objective: To determine whether different brands of intravenous immunoglobulin (IVIG) administered to children with Kawasaki disease (KD) result in different outcomes. Study design: We analyzed children with KD and divided them into 4 groups according to the brand of IVIG. A coronary artery abnormality (CAA) was defined as having a lumen diameter (inner border to inner border) of ≥3 mm in KD cases <5 years old and ≥4 mm in cases ≥5 years old, and giant aneurysm was defined as a lumen diameter ≥8 mm. Patients were considered nonresponsive to IVIG therapy if fever persisted longer than 2 days after completion of treatment and needed retreatment with IVIG. Results: We collected 437 cases, 29 (6.6%) were nonresponsive, 17 (3.9%) had CAA at convalescence, and 3 (0.7%) had giant aneurysm, 2 of whom had development of myocardial infarcts. Patients receiving Brand C IVIG, prepared with β-propiolactone, had higher rates (10%, 9/93, P = .01) of CAA at convalescence and nonresponsiveness (13%, 12/93, P = .001); giant aneurysm occurred in 3/93 (3%) receiving Brand C IVIG and in 0/344 who received the other 3 brands (P = .008). Conclusions: IVIG, prepared with β-propiolactone, was most significantly associated with nonresponsiveness, CAA at convalescence, and giant aneurysm. Physicians should be cautious when using IVIG prepared with β-propiolactone or enzyme digestion to treat KD.
頁(從 - 到)38-43
期刊Journal of Pediatrics
出版狀態已發佈 - 1月 2006

ASJC Scopus subject areas

  • 兒科、圍產兒和兒童健康


深入研究「Clinical responses of patients with Kawasaki Disease to different brands of intravenous immunoglobulin」主題。共同形成了獨特的指紋。